Genelux Corporation Appoints Catherine J. Mackey, PhD to Board of Directors
SAN DIEGO, Aug. 4, 2011 /PRNewswire/ -- Genelux Corporation, a privately held, clinical stage biopharmaceutical company developing diagnostic and therapeutic solutions for cancer and inflammatory diseases, today announced the appointment of Dr. Catherine J. Mackey, long-time Pfizer executive, to the Company's Board of Directors.
"In a career defined by excellence at every level, Dr. Mackey brings a unique set of skills and attributes that we believe will significantly complement and further strengthen the Genelux Board," said Aladar A. Szalay, Chairman and Chief Executive Officer. "Her 28 years of industry experience will be a valuable asset, particularly as we advance the Genelux product pipeline into later stage trials and prepare the company for the next stage of growth. Dr. Mackey's executive experience within a world class pharmaceutical R&D organization will help us to preserve the core of scientific innovation that has characterized Genelux Corporation. I am honored to welcome Catherine Mackey as our third outside Director".
Dr. Mackey is the founder and CEO of MindPiece Partners, a management consulting firm, and the former Sr. Vice President of Worldwide Research and Development for Pfizer Inc. She has 28 years of experience in the life science industry.
After receiving her B.S. and Ph.D. degrees in microbiology from Cornell University, Dr. Mackey spent the first part of her career in agricultural biotechnology. She worked her way up from bench scientist to Vice President and head of Research and Development for DEKALB Genetics Corporation. She was member of DEKALB's executive team which sold the company to Monsanto in 1998. Dr. Mackey joined Pfizer in 1999 to lead Genomic and Proteomic Sciences for human health in Groton, CT. Soon she was appointed Vice President and head of Strategic Alliances and in 2001 she was appointed Sr. Vice President of Pfizer Global R&D and Director of Pfizer La Jolla – a position she held fo